Christopher Cogle
Professor University of Florida
- Gainesville FL
Dr. Christopher Cogle is a physician and health policy expert on Medicaid, population health and government innovation in healthcare.
Biography
Areas of Expertise
Social
Articles
Leveraging Medicaid Claims to Map Complex Chronic Conditions for Emergency Preparedness
Journal of Public Health Management and PracticeHall, et al.
2026-03-01
Populations with complex chronic conditions (CCCs), especially those reliant on medical technology, face disproportionate risks during disasters. Medicaid enrollees make up a large portion of these vulnerable populations, yet states often lack rapid identification systems to inform disaster planning. Florida Medicaid developed a claims-based method to identify enrollees with CCCs, including those dependent on medical technology, to support emergency preparedness and response activities.
Impact Of Housing Support Services For Medicaid Enrollees With Serious Mental Illness, Substance Use Disorder
Health Affairs (Millwood)Bruefach, et al.
2026-01-01
In 2019, pursuant to a Section 1115 waiver, Florida launched a Statewide Medicaid Managed Care housing assistance pilot to foster housing stability and reduce preventable health care use in adults with serious mental illness (SMI) or substance use disorder (SUD). We conducted a retrospective cohort study to examine the relationship between four housing support services provided in the pilot (transitional housing support, tenancy support, peer support, and crisis management) and health care use and health outcomes among 1,300 pilot enrollees during the period December 2017-June 2024.
Medicaid Payment Policy and Colorectal Cancer Screening Rates
JAMA Network OpenHall, et al.
2025-07-01
This comparative effectiveness study evaluates the association between a new Medicaid payment policy and rates of cancer screening in Florida.
Medicaid and the Promise for Cure
JAMA PediatricsMiller, et al.
2025-02-01
Cell and gene therapies are revolutionizing the treatment landscape for children and adults with rare diseases and can be life-changing for patients and their families. Successful implementation of these new therapies into clinical practice depends on their accessibility and affordability, particularly through publicly funded Medicaid agencies, which cover many children and adults with rare diseases.
